Gland Pharma Q3 FY26: Revenue Up 22% YoY to ₹16,954 Crore, Adj. PAT Grows 37%
Gland Pharma reported Q3 FY26 revenue of ₹16,954 crore, up 22% YoY. Adjusted PAT increased by 37% to ₹2,797 crore. Adjusted EBITDA grew 25% to ₹4,490 crore. R&D expenses increased to ₹6.5 crore. The company launched nine molecules in the US.
The announcement details significant financial performance improvements, including substantial revenue and profit growth, which are material to investors.
The company reported strong year-on-year growth in revenue, adjusted EBITDA, and adjusted PAT, along with positive commentary from the executive chairman and CEO regarding performance and future outlook.
Gland Pharma Limited announced its financial results for the third quarter ended December 31, 2025, reporting a strong performance with a 22% year-on-year increase in revenue from operations, reaching ₹16,954 crore. Adjusted PAT saw a significant growth of 37% YoY to ₹2,797 crore. The company's adjusted EBITDA also grew by 25% YoY to ₹4,490 crore, with an improved margin of 26%.
Mr. Srinivas Sadu, Executive Chairman, highlighted the disciplined execution across businesses, driven by robust revenue growth and healthy EBITDA margins. He expressed confidence in sustaining momentum through new product launches, CDMO contract ramp-ups, and operational efficiencies. Mr. Shyamakant Giri, CEO, attributed the performance to consistent execution, double-digit growth in key markets like the US and Europe, and margin improvements, with Cenexi achieving breakeven and strong traction in the base business.
Consolidated revenue for the nine months ended December 31, 2025, increased by 12% to ₹46,879 crore. R&D investments in the quarter rose to ₹650 million (approximately ₹6.5 crore) from ₹437 million in the previous year, reflecting increased product development and filings. The company launched nine molecules in the USA and two in other regulated markets during the quarter. Furthermore, Gland Pharma filed nine ANDAs in the US, with four approvals, and three new filings in other regulated markets.
In its Base Business segment, revenue grew by 16% YoY to ₹11,790 crore, with adjusted EBITDA increasing by 11% to ₹4,342 crore. The Cenexi segment reported revenue of ₹5,164 crore (€50 Mn), a 39% YoY increase, and achieved breakeven with a positive EBITDA of ₹148 crore (€1.4 Mn).
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.